Evora Biosciences – A Pioneering European Exosome Therapeutics Spin-Off
28 pages · PDF · 16 August 2025 · Licensed single-user copy, watermarked to the buyer
€499 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
Evora Biosciences is emerging as a compelling example of Europe’s push into cutting-edge biotechnology for regenerative medicine. Founded in 2020 as a spin-off of the Université de Paris and INSERM, this French startup has set its sights on a novel “off-the-shelf” therapy using exosomes – nanoscale vesicles secreted by stem cells – to heal complex internal wounds.
Its lead program, EVOGEX, delivers cell-derived exosomes in a temperature-responsive gel to treat severe digestive fistulas without the complexities of live cell transplants . These difficult-to-treat fistulas affect an estimated 1.2 million patients in Europe and the US , yet current solutions are limited.
Key questions this report answers
- What exosome-based 'off-the-shelf' therapeutics does Evora Biosciences develop, notably its EVOGEX program for digestive fistulas?
- How mature is Evora's temperature-responsive exosome gel relative to live-cell transplant alternatives?
- What partnerships, Universite de Paris/INSERM origins and markets support the French spin-off?
- What capability gaps and dependencies affect Evora's regenerative-medicine platform?
Inside this report
- 1. Corporate Identity & Legal Structure
- 2. Strategic Business Profile
- 3. Technology Portfolio Mapping
- 4. Technology Readiness Assessment
- 5. European Strategic Program Participation
- 6. Academic & Research Origins
- 7. Dual-Use Applications & European Market Strategy
- 8. Strategic Partnerships & European Industrial Alliances
- 9. European Market Focus & Operational Domains
- 10. Intellectual Property & European Innovation Assets
- 11. Leadership & European Technical Expertise
- 12. Capability and Gap Analysis
- 13. Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening Evora Biosciences, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Methodology & sources
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; the report reflects them as of its publication date (16 August 2025).
Format & delivery
28-page PDF, watermarked to you (name, e-mail, order number on every page). Delivered immediately after checkout on the confirmation page and by e-mail; the personal link is valid for 72 hours and up to 5 downloads (re-issued on request). Guest checkout — no account required. Single-user licence: see the Terms of Sale.
The full analysis, not the summary
The public briefing linked above tells you what this report found; the report itself shows the full evidence and reasoning behind it, section by section. It is the complete, dated document from the DFM research desk — sources cited, delivered as a licensed PDF you can keep and cite in your own work.
Related on DFM
More Tactical reports · Military Medical Tech · Free summary of this report · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →